This handbook adopts a broad perspective on the use of animals in the early part of the drug development process, including regulatory rules and limitations, as well as numerous examples from real–life drug development projects.
After a general introduction to the topic, the expert contributors discuss the basic considerations of using animal models, including ethical issues. The main part of the book systematically surveys the most important disease areas for current drug development, from cardiovascular to endocrine, gastro–intestinal, urogenital disorders, cancer, migraine and chronic pain, and from infectious to neuropsychiatric diseases. For each area, the availability of animal models for target validation, hit finding and lead profiling is reviewed, backed by numerous examples of both successes and failures among the use of animal models. The whole is rounded off with a discussion of perspectives and challenges.
Key knowledge for drug researchers in industry as well as academia.
ANIMAL MODELS IN DRUG DISCOVERY
Alternative models to in vivo animal models in Drug Discovery
Regulatory issues: Requirements for Safety and Toxicology assessment
Ethical issues/guidelines concerning in vivo animal models.
Genetic/transgenic animal models: generation and use in drug discovery
In vivo imaging of animal models
ANIMAL MODELS IN SPECIFIC AREAS OF DRUG DISCOVERY
Psychiatric Disorders (Anxiety, Depression, Apathy, Psychosis and sleep)
Pain (Migraine, visceral, cancer, postoperative, inflammatory, musculoskeletal and neuropathic pain)
Nutrition/eating disorder, Obesity, Metabolic syndrome
Neurological Disorders (demyelination, cognitive diseases, dementias, neurotrauma, movement disorders)
Renal and Genitourinary Disorders
PERSPECTIVES AND CHALLENGES